Fast Company has unveiled its list of Top 10 Most Innovative Companies in Biotech recognising companies that exemplify the best in the business and innovation in their respective fields. 

The list aims to recognise pioneering companies across 36 categories, from artificial intelligence to wellness. More than three dozen Fast Company editors, reporters, and contributors surveyed thousands of companies to create these lists. 

The full list is as follows: 

  1. Novartis
  2. OneOme
  3. GE Healthcare
  4. Syapse
  5. Sophia Genetics
  6. Spark Therapeutics
  7. Biogen
  8. Synthego
  9. WuXi NextCode
  10. Gingko Bioworks

It is worth noting the work of SOPHiA GENETICS who have slid in at fifth place. Its AI platform helps clinicians effectively diagnose and treat their patients. The company’s Artificial Intelligence, SOPHiA solves the complexity of genomic data analysis by accurately detecting disease-causing mutations in five areas, including, hereditary cancer, oncology, cardiology, metabolism, and pediatrics. To date, the technology has been deployed across over 400 hospitals in 55 countries and has helped to better diagnose over 177,000 patients worldwide. 

In addition, emerging global standard platform for genomic data, WuXi NextCode will no doubt be celebrating this achievement too, ranking at ninth place.  This distinction specifically recognises the success and benefit to patients of the RareCODE rare disease testing platform in China, which was launched approximately one year ago at Fudan Children’s Hospital in Shanghai. 

Amongst its achievements, it was the first platform to apply global gold standard genomics to the diagnosis of rare disease, at scale, in China. As a result, it is enabling the rapid and accurate diagnosis of thousands of rare disease patients, including in the neonatal intensive care unit, and pointing the way to effective therapies for many who would previously have remained undiagnosed. 

“In little over a year, RareCODE and our partnership with Fudan has grown to be one of the largest-scale genome-based rare disease diagnostic efforts in the world,” explained Hannes Smarason, CEO of WuXi NextCODE. 

“By definition, solving rare disease requires harnessing and deploying massive genomic datasets on a global scale. Our platform is uniquely powered to do that, allowing clinicians and researchers in the preeminent rare disease programs in the US, Europe, and the Middle East to access best-in-class interpretation capabilities backed by an unrivaled global knowledgebase available in real time, online.

“But you can’t have a global platform without China. That’s where we and Fudan have led the way, and we expect to expand that effort both in China and globally in 2018,” he added. 

Materials provided by SOPHiA GENETICS and WuXi NextCode. Note: Content may be edited for style and length.